Showing results (301-310 of 324) with videos related to

Sort By:
Pageof 33
BMC Cancer|April 4, 2025
A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)Jaume Capdevila, Virginia Pubul, Urbano Anido, et al.
Cancer Immunology, Immunotherapy : CII|May 29, 2023
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 studyMatteo Santoni, Zin W Myint, Thomas Büttner, et al.
Acta Neuropathologica Communications|October 25, 2021
Ex vivo MRI atlas of the human medial temporal lobe: characterizing neurodegeneration due to tau pathologySadhana Ravikumar, Laura E M Wisse, Sydney Lim, et al.
Antibiotics (Basel, Switzerland)|August 27, 2021
The Role of Statins on Helicobacter pylori Eradication: Results from the European Registry on the Management of H. pylori (Hp-EuReg)María Caldas, Ángeles Pérez-Aisa, Bojan Tepes, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 13, 2019
Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of PatientsAdrian G McNicholl, Dmitry S Bordin, Alfredo Lucendo, et al.
European Urology Focus|July 30, 2025
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 StudyFrancesco Massari, Veronica Mollica, Ray Manneh Kopp, et al.
Helicobacter|July 14, 2020
Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg)Olga P Nyssen, Angeles Perez-Aisa, Luis Rodrigo, et al.
European Journal of Cancer (Oxford, England : 1990)|September 23, 2025
177Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 studyPhilipp Mandel, Daniel Groener, Giulia Follacchio, et al.
Minerva Urology and Nephrology|June 23, 2026
Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 studyPasquale Rescigno, Tarek Taha, Maria J Fita, et al.
Biorxiv : the Preprint Server for Biology|February 24, 2025
Developing an anatomically valid segmentation protocol for anterior regions of the medial temporal lobe for neurodegenerative diseasesNiyousha Sadeghpour, Sydney A Lim, Anika Wuestefeld, et al.
Pageof 33